<i>TYK2</i>、<i>STAT3</i>与无功能性垂体腺瘤侵袭性相关性研究

doi:10.3877/cma.j.issn.2095-123X.2022.01.004

中华脑科疾病与康复杂志(电子版) ›› 2022, Vol. 12 ›› Issue (01) : 27 -31. doi: 10.3877/cma.j.issn.2095-123X.2022.01.004

临床研究

TYK2、STAT3与无功能性垂体腺瘤侵袭性相关性研究

阿卜杜喀迪尔·牙森¹, 巴图², 张诚³, 麦麦提依明·托合提³, 杨小朋³, 吴永刚³^,^†(

)

^1. 832000　石河子，石河子大学医学院
^2. 830000　乌鲁木齐，新疆维吾尔自治区人民医院病理科
^3. 830000　乌鲁木齐，新疆维吾尔自治区人民医院神经外科

收稿日期:2021-12-29 出版日期:2022-02-15
通信作者: 吴永刚
基金资助:
新疆维吾尔自治区自然科学基金(2016D01C108)

Correlation between the expression of TYK2 and STAT3 in non-functioning pituitary adenomas and invasiveness

Yasen Abudukadier¹, Tu Ba², Cheng Zhang³, Tuoheti Maimaitiyiming³, Xiaopeng Yang³, Yonggang Wu³^,^†()

^1. School of Medicine, Shihezi University, Shihezi 832000, China
^2. Department of Pathology, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, China
^3. Department of Neurosurgery, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, China

Received:2021-12-29 Published:2022-02-15
Corresponding author: Yonggang Wu

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

阿卜杜喀迪尔·牙森, 巴图, 张诚, 麦麦提依明·托合提, 杨小朋, 吴永刚. TYK2、STAT3与无功能性垂体腺瘤侵袭性相关性研究[J/OL]. 中华脑科疾病与康复杂志(电子版), 2022, 12(01): 27-31.

Yasen Abudukadier, Tu Ba, Cheng Zhang, Tuoheti Maimaitiyiming, Xiaopeng Yang, Yonggang Wu. Correlation between the expression of TYK2 and STAT3 in non-functioning pituitary adenomas and invasiveness[J/OL]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2022, 12(01): 27-31.

目的

研究酪氨酸激酶2（TYK2）和信号转导因子和转录激活因子3（STAT3）在无功能性垂体腺瘤（NFPA）的表达与侵袭性的相关性。

方法

收集新疆维吾尔自治区人民医院神经外科自2020年6月至2021年5月收治的24例NFPA患者的临床资料和手术标本，根据术前核磁检查和术中所见情况分为侵袭性组和非侵袭性组，每组12例。用qRT-PCR、Western blot及免疫组化等方法检测2组患者NFPA组织中的TYK2和STAT3表达量，分析其表达量与NFPA侵袭性的相关性。

结果

qRT-PCR、Western blot及免疫组化结果均显示，与非侵袭组相比，侵袭组NFPA中TYK2低表达、STAT3高表达，差异均有统计学意义（P<0.05）。

结论

TYK2在侵袭性NFPA中表达下调，其低表达可能与NFPA侵袭性相关；STAT3在侵袭性NFPA中表达上调，其高表达可能与NFPA侵袭性相关。

关键词: 无功能性垂体腺瘤, 酪氨酸激酶2, 信号转导因子和转录激活因子3, 侵袭性

Objective

To investigate the correlation between the expression of tyrosine kinase 2 (TYK2) and signal transducers and activators of transcription 3 (STAT3) in non-functioning pituitary adenoma (NFPA) and invasiveness.

Methods

Clinical data and surgical specimens of 24 patients with NFPA treated in our hospital from June 2020 to May 2021 were collected and divided into invasive and non-invasive NFPA groups based on their pre-operative imaging and intra-operative information, comprising 12 patients for each group. TYK2 and STAT3 expressions in the NFPA tissues of the two groups were measured by quantitative real-time polymerase chain reaction (qRT-PCR), immunohistochemistry (IHC) and Western blotting, and the correlation among their expressions in NFPA and invasiveness was analysed.

Results

The results of qRT-PCR, Western blot and immunohistochemistry showed that low TYK2 and high STAT3 expressed in the NFPA of the invasive group compared to the non-invasive group (P<0.05).

Conclusion

The expression of TYK2 in invasive NFPA is down-regulated and its low expression may be associated with NFPA invasiveness; The expression of STAT3 in invasive NFPA is up-regulated and its high expression may be associated with NFPA invasiveness.

Key words: Non-functioning pituitary adenoma, Tyrosine kinase 2, Signal transducers and activators of transcription 3, Invasiveness

图1 2组患者TYK2和STAT3基因相对表达量对比与非侵袭性组比较，^aP <0.05

图2 2组患者肿瘤组织中TYK2、STAT3蛋白表达对比A：Western blot结果；B：条带灰度值比较；与非侵袭性组比较，^aP<0.05

图3 TYK2和STAT3蛋白表达水平（免疫组化，×400）

图4 非侵袭组和侵袭组中TYK2和STAT3蛋白表达水平与非侵袭性组比较，^aP<0.05

[1]	Yu SY, Hong LC, Feng J, et al. Integrative proteomics and transcriptomics identify novel invasive-related biomarkers of non-functioning pituitary adenomas[J]. Tumour Biol, 2016, 37(7): 8923-8930.
[2]	Guo J, Wang Z, Miao Y, et al. A two-circRNA signature predicts tumour recurrence in clinical non-functioning pituitary adenoma[J]. Oncol Rep, 2019, 41(1): 113-124.
[3]	Fu P, He YS, Cen YC, et al. Microneurosurgery and subsequent gamma knife radiosurgery for functioning pituitary macroadenomas or giant adenomas: one institution's experience[J]. Clin Neurol Neurosurg, 2016, 145: 8-13.
[4]	杨昕，唐哲，张鹏,等. JAK/STAT信号通路在肺癌中的研究进展[J].中国肺癌杂志, 2019, 22(1): 45-51.
[5]	Bousoik E, Montazeri Aliabadi H. "Do we know Jack" about JAK? A closer look at JAK/STAT signaling pathway[J]. Front Oncol, 2018, 8: 287.
[6]	Wöss K, Simonović N, Strobl B, et al. TYK2: an upstream kinase of STATs in cancer[J]. Cancers (Basel), 2019, 11(11): 1728.
[7]	Wu P, Wu D, Zhao L, et al. Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis[J]. Oncotarget, 2016, 7(15): 19863-19883.
[8]	Owen KL, Brockwell NK, Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression[J]. Cancers (Basel), 2019, 11(12): 2002.
[9]	Borcherding DC, He K, Amin NV, et al. TYK2 in cancer metastases: genomic and proteomic discovery[J]. Cancers (Basel), 2021, 13(16): 4171.
[10]	Huynh J, Etemadi N, Hollande F, et al. The JAK/STAT3 axis: a comprehensive drug target for solid malignancies[J]. Semin Cancer Biol, 2017, 45: 13-22.
[11]	Ou A, Ott M, Fang D, et al. The role and therapeutic targeting of JAK/STAT signaling in glioblastoma[J]. Cancers (Basel), 2021, 13(3): 437.
[12]	Leitner NR, Witalisz-Siepracka A, Strobl B, et al. Tyrosine kinase 2-surveillant of tumours and bona fide oncogene[J]. Cytokine, 2017, 89: 209-218.
[13]	Sang QX, Man YG, Sung YM, et al. Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis[J]. Clin Exp Metastasis, 2012, 29(2): 143-153.
[14]	Feng J, Yu SY, Li CZ, et al. Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas[J]. Mol Cell Endocrinol, 2016, 436: 195-203.
[15]	Shen X, Liu Q, Xu J, et al. Correlation between the expression of interleukin-6, STAT3, E-Cadherin and N-Cadherin protein and invasiveness in nonfunctional pituitary adenomas[J]. J Neurol Surg B Skull Base, 2021, 82(Suppl 3): e59-e69.
[16]	Coskun M, Salem M, Pedersen J, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease[J]. Pharmacol Res, 2013, 76: 1-8.
[17]	Okabe N, Fujiwara M, Tachibana K, et al. STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior[J]. Gen Thorac Cardiovasc Surg, 2021, 69(11): 1482-1491.

[1]	冯丹, 姜尔烈. 血液病患者侵袭性肺曲霉菌病研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2022, 16(03): 145-149.
[2]	王楠, 张怡, 安明. 侵袭性鼻-眼-脑型毛霉菌病一例[J/OL]. 中华实验和临床感染病杂志(电子版), 2022, 16(02): 137-142.
[3]	宋瑛, 宋江勤, 胡福英, 李华顺, 田友军, 丁妍, 周君阳. 宏基因二代测序协助诊断毛霉菌病一例并文献复习[J/OL]. 中华实验和临床感染病杂志(电子版), 2022, 16(01): 54-59.
[4]	钱永兵, 杭化莲, 张灏旻, 邓羽霄, 陈小松, 夏强. 慢加急性肝衰竭肝移植术后早期并发播散性曲霉病一例[J/OL]. 中华移植杂志(电子版), 2022, 16(05): 306-308.
[5]	刘雪峰, 韩海峰, 杨硕, 逯景辉. 腹腔镜腹壁侵袭性纤维瘤病切除联合腹壁重建：单中心经验总结[J/OL]. 中华疝和腹壁外科杂志(电子版), 2023, 17(04): 374-379.
[6]	刘磊, 张琪, 范兴彪. 基于放射性特征预测肺结节侵袭性的临床应用[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(06): 880-882.
[7]	陈勇, 任建伟, 朱光发, 刘玉磊, 吴绍芹. 非移植患者侵袭性肺曲霉病32例临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(06): 809-813.
[8]	孟原竹, 蒋国路, 陈小兵, 蒋莉. 肺结核合并侵袭性肺曲霉感染临床特征及危险因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(04): 541-543.
[9]	吴娇艳, 鹿静雅, 符萌, 刘影. 侵袭性真菌性肺炎MSCT影像特征及与IL-17、IL-23相关性[J/OL]. 中华肺部疾病杂志(电子版), 2022, 15(06): 835-837.
[10]	李博, 胡刚, 邱文龙, 庄孟, 梅世文, 汤坚强, 王锡山. 腹腔镜下盆腔腹膜后肿瘤经肛门取标本手术（附视频）[J/OL]. 中华结直肠疾病电子杂志, 2023, 12(01): 85-88.
[11]	宫继斌, 刘光凤, 刘宝, 闫美辰, 庞明敏, 许玥, 孟婷钰, 许娜娜, 范少华, 王昊. 病毒性肺炎合并侵袭性肺曲霉病的研究进展[J/OL]. 中华重症医学电子杂志, 2023, 09(04): 385-390.
[12]	王守森, 方翌, 冯添顺, 魏梁锋. 深度学习模型在侵袭性垂体腺瘤诊疗中的应用[J/OL]. 中华脑科疾病与康复杂志(电子版), 2023, 13(06): 382-384.
[13]	黄敏, 陈雪芬, 申舟如, 何志义, 白晶, 李梅华, 杨美玲, 邓静敏. 混合型肺曲霉病21例临床特征分析[J/OL]. 中华临床医师杂志(电子版), 2022, 16(12): 1217-1223.
[14]	朱镭, 朱庆义. 金氏菌属：引起婴幼儿侵袭性传染病的新发病原体[J/OL]. 中华临床实验室管理电子杂志, 2024, 12(04): 229-237.
[15]	张芳芳, 李军, 赵玉洁, 于彤, 宁春平. 侵袭性血管黏液瘤的影像学特征并文献复习[J/OL]. 中华诊断学电子杂志, 2024, 12(04): 254-259.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Correlation between the expression of TYK2 and STAT3 in non-functioning pituitary adenomas and invasiveness

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Correlation between the expression of TYK2 and STAT3 in non-functioning pituitary adenomas and invasiveness